(S (NP (NP (DT An) (JJ innovative) (NN approach)) (SBAR (S (VP (TO to) (VP (VB analyze) (NP (NP (DT the) (NN complexity)) (PP (IN of) (S (VP (VBG translating) (NP (JJ novel) (JJ molecular) (NNS entities) (CC and) (NX (NNS nanomaterials))) (PP (IN into) (NP (JJ pharmaceutical) (NNS alternatives))))))))))) (PRN (-LRB- -LRB-) (FW i.e.) (, ,) (NP (NP (NN knowledge) (NN translation)) (, ,) (NP (NNP KT))) (-RRB- -RRB-))) (VP (VBZ is) (VP (VBN discussed))) (. .))
(S (ADVP (NNP First)) (, ,) (NP (NP (NP (DT some) (JJ key) (NNS concepts)) (PP (IN on) (NP (NP (DT the) (NN organization) (CC and) (NN translation)) (PP (IN of) (NP (DT the) (JJ biomedical) (NN knowledge)))))) (PRN (-LRB- -LRB-) (NP (NP (NN paradigms)) (, ,) (NP (RB homophily)) (, ,) (NP (NN power) (NN law) (NNS distributions)) (, ,) (NP (NN hierarchy)) (, ,) (NP (NN modularity)) (, ,) (CC and) (NP (NN research) (NNS fronts))) (-RRB- -RRB-))) (VP (VBP are) (VP (VBN reviewed))) (. .))
(S (ADVP (RB Then)) (, ,) (NP (PRP we)) (VP (VBP propose) (NP (NP (DT a) (NN model)) (PP (IN for) (NP (NP (NP (DT the) (NN knowledge) (NN translation)) (PRN (-LRB- -LRB-) (NP (NNP KT)) (-RRB- -RRB-))) (PP (IN in) (NP (NNP Drug) (NNP Discovery))))) (SBAR (WHNP (IN that)) (S (VP (VBZ considers) (NP (NP (DT the) (NN complexity)) (PP (IN of) (NP (JJ interdisciplinary) (NN communication))))))))) (. .))
(S (ADVP (RB Specifically)) (, ,) (NP (PRP we)) (VP (VBP address) (NP (NP (CD two) (ADJP (RB highly) (JJ relevant)) (NNS aspects)) (: :) (SBAR (S (VP (CD 1) (-RRB- -RRB-) (S (NP (DT A) (JJ successful) (NNP KT)) (VP (VBZ requires) (NP (NP (DT the) (NN emergence)) (PP (IN of) (NP (NP (JJ organized) (NNS bodies)) (PP (IN of) (NP (ADJP (JJ inter-and) (JJ transdisciplinary)) (NN research)))))))))) (, ,) (CC and) (SINV (CD 2) (-RRB- -RRB-) (NP (NP (DT The) (ADJP (JJ hierarchical) (CC and) (JJ modular)) (JJ topological) (NN organization)) (PP (IN of) (NP (NP (DT these) (NNS bodies)) (PP (IN of) (NP (NN knowledge)))))))))) (. .))
(S (NP (PRP We)) (VP (VBD focused) (PP (IN on) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (JJ previously-published) (NNS studies)) (PP (IN on) (NP (NNP KT))) (SBAR (WHNP (WDT which)) (S (VP (VBP rely) (PP (IN on) (NP (NP (DT a) (NN combination)) (PP (IN of) (NP (NP (NN network) (NN analysis)) (CC and) (NP (NP (JJ computer-assisted) (NN analysis)) (PP (IN of) (NP (NP (DT the) (NNS contents)) (PP (IN of) (NP (NP (JJ scientific) (NN literature)) (CC and) (NP (NNS patents))))))))))))))))))) (. .))
(S (NP (DT The) (VBN selected) (NNS studies)) (VP (VBP provide) (NP (NP (NP (DT a) (NN duo)) (PP (IN of) (NP (JJ complementary) (NNS perspectives)))) (: :) (NP (NP (NP (NP (DT the) (NN demand)) (PP (IN of) (NP (NN knowledge)))) (PRN (-LRB- -LRB-) (NP (NP (JJ cervical) (NN cancer)) (CC and) (NP (NNP Ebola) (VBP hemorrhagic) (NN fever))) (-RRB- -RRB-))) (CC and) (NP (NP (DT the) (NN supply)) (PP (IN of) (NP (NN knowledge))) (PRN (-LRB- -LRB-) (NP (NP (NP (NNS liposomes) (CC and) (NNS nanoparticles)) (SBAR (S (VP (TO to) (VP (VB treat) (NP (NN cancer))))))) (CC and) (NP (NP (DT the) (JJ paradigmatic) (NNP Doxil)) (, ,) (NP (NP (DT the) (JJ first) (NN nanodrug)) (SBAR (S (VP (TO to) (VP (VB be) (VP (VBN approved))))))))) (-RRB- -RRB-)))))) (. .))
